ATE414080T1 - Synthese von antidiabetischen rosiglitazonderivaten - Google Patents

Synthese von antidiabetischen rosiglitazonderivaten

Info

Publication number
ATE414080T1
ATE414080T1 AT05740577T AT05740577T ATE414080T1 AT E414080 T1 ATE414080 T1 AT E414080T1 AT 05740577 T AT05740577 T AT 05740577T AT 05740577 T AT05740577 T AT 05740577T AT E414080 T1 ATE414080 T1 AT E414080T1
Authority
AT
Austria
Prior art keywords
rosiglitazone
antidiabetic
synthesis
derivatives
pharmaceutically acceptable
Prior art date
Application number
AT05740577T
Other languages
English (en)
Inventor
Dharmaraj Ramachandra Rao
Rajendra Narayanrao Kankan
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Application granted granted Critical
Publication of ATE414080T1 publication Critical patent/ATE414080T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
AT05740577T 2004-05-05 2005-05-03 Synthese von antidiabetischen rosiglitazonderivaten ATE414080T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0410013A GB2413795A (en) 2004-05-05 2004-05-05 Process for the preparation of rosiglitazone

Publications (1)

Publication Number Publication Date
ATE414080T1 true ATE414080T1 (de) 2008-11-15

Family

ID=32482705

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05740577T ATE414080T1 (de) 2004-05-05 2005-05-03 Synthese von antidiabetischen rosiglitazonderivaten

Country Status (14)

Country Link
US (1) US7598387B2 (de)
EP (1) EP1756099B1 (de)
JP (1) JP2007536358A (de)
KR (1) KR20070014191A (de)
AT (1) ATE414080T1 (de)
AU (1) AU2005238282A1 (de)
CA (1) CA2565665A1 (de)
DE (1) DE602005011004D1 (de)
ES (1) ES2315867T3 (de)
GB (1) GB2413795A (de)
NZ (1) NZ551126A (de)
PT (1) PT1756099E (de)
WO (1) WO2005105794A1 (de)
ZA (1) ZA200609147B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151711A1 (en) 2009-06-25 2010-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds
ES2691671T3 (es) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
JP5546372B2 (ja) * 2010-06-30 2014-07-09 積水メディカル株式会社 ベンジルヒダントイン化合物の製造法
US9034867B2 (en) 2011-03-18 2015-05-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
CA2858787C (en) 2011-12-15 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of tertiary amine compounds
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
CA2867137C (en) 2012-03-19 2020-12-08 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
JP7384812B2 (ja) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド アリピプラゾール投与戦略

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306228B1 (de) * 1987-09-04 1999-11-17 Beecham Group Plc Substituierte Thiazolidindionderivate
ES2007537A6 (es) * 1988-07-21 1989-06-16 Cenavisa S A Procedimiento para la preparacion de derivados neutronsolubles de la sulfametoxipiridazina y del sulfametoxazol a partir de aldehidos aromaticos.
KR100624585B1 (ko) * 1998-05-05 2006-09-18 일라이 릴리 앤드 캄파니 카르복스알데히드의 정제
HU225919B1 (en) * 1999-12-18 2007-12-28 Richter Gedeon Nyrt Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
WO2002051823A1 (en) * 2000-12-26 2002-07-04 Torrent Pharmaceuticals Ltd Process for the preparation of rosiglitazone maleate

Also Published As

Publication number Publication date
GB2413795A (en) 2005-11-09
JP2007536358A (ja) 2007-12-13
US7598387B2 (en) 2009-10-06
EP1756099A1 (de) 2007-02-28
KR20070014191A (ko) 2007-01-31
WO2005105794A1 (en) 2005-11-10
PT1756099E (pt) 2009-02-03
EP1756099B1 (de) 2008-11-12
CA2565665A1 (en) 2005-11-10
GB0410013D0 (en) 2004-06-09
ES2315867T3 (es) 2009-04-01
NZ551126A (en) 2010-10-29
DE602005011004D1 (de) 2008-12-24
ZA200609147B (en) 2007-06-27
US20070191611A1 (en) 2007-08-16
AU2005238282A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
ATE414080T1 (de) Synthese von antidiabetischen rosiglitazonderivaten
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
CY1107238T1 (el) Παρασκευη μιας πολυμορφικης μορφης ενος παραγωγου θειαζολιδινοδιονης
WO2005105749A3 (en) Process for making montelukast and intermediates therefor
EP1541561A4 (de) Pyrazolderivate und verfahren zu deren herstellung
HUP0103988A2 (en) New d3-dopamine receptor selective piperazine and piperidine compounds, process for their preparation, their and pharmaceutical compositions containing them
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
WO2007091009A3 (en) Preparation of delmopinol
ZA200710145B (en) Method for the production of 5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl-benzofuran-2-carboxamide
IL183663A0 (en) Process for the preparation of a 2-ethylaminopyridine derivative
NO20073701L (no) Nye fremgangsmater for fremstilling av et 2H-kromen
IL180985A0 (en) N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine 2 methanesulfonic acid salt
TW200716582A (en) Process for making a pharmaceutical compound
CA2437501A1 (en) Process for the manufacture of phenylacetic acid derivatives
NO20043611L (no) Fremgangsmate for fremstilling av HMG-COA reduktaseinhibitorer
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner
DK1948626T3 (da) Fremgangsmåde til fremstilling af delmopinol og derivater deraf
DK1877370T3 (da) Fremgangsmåde til fremstilling af hydrazon-derivater
Avenell et al. Heterocyclic analogues of 2-aminotetralins with high affinity and selectivity for the dopamine D3 receptor
RS53062B (en) PREPARATION PROCESS 4 - [(1,6-Dihydro-6-oxo-2-pyrimidinyl) AMINO BENZONITRILA
UY24886A1 (es) Tiazolidindiona
NO20010265D0 (no) 3-(1-hydroksy-pentyliden)-5-nitro-3H-benzofuran-2-on, fremgangsmåte for fremstilling og anvendelse derav
WO2003057131A3 (en) Novel process for the preparation of trans-3- ethyl-2,5- dihydro-4- methyl-n-[2-[ 4-[[[[(4-methyl cyclohexyl) amino]carbonyl] amino]sulfonyl] phenyl]ethyl] -2-oxo-1h-pyrrole -1-carboxamide
WO2006013049A3 (en) Benzyloxy derivatives as maob inhibitors
DK1465917T3 (da) Mellemprodukter for LHRH-antagonistsyntesen, fremgangsmåder til deres fremstilling samt fremgangsmåder til fremstilling af LHRH-antagonister

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties